JP2019526635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526635A5 JP2019526635A5 JP2019532214A JP2019532214A JP2019526635A5 JP 2019526635 A5 JP2019526635 A5 JP 2019526635A5 JP 2019532214 A JP2019532214 A JP 2019532214A JP 2019532214 A JP2019532214 A JP 2019532214A JP 2019526635 A5 JP2019526635 A5 JP 2019526635A5
- Authority
- JP
- Japan
- Prior art keywords
- type
- antigen
- present
- amount
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 116
- 102000036639 antigens Human genes 0.000 claims 105
- 108091007433 antigens Proteins 0.000 claims 105
- 229960005486 vaccine Drugs 0.000 claims 53
- 239000000203 mixture Substances 0.000 claims 24
- 241000991587 Enterovirus C Species 0.000 claims 20
- 241000274177 Juniperus sabina Species 0.000 claims 19
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 19
- 102100021503 ATP-binding cassette sub-family B member 6 Human genes 0.000 claims 17
- 229960002885 histidine Drugs 0.000 claims 15
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims 13
- 241000606768 Haemophilus influenzae Species 0.000 claims 13
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 13
- 229910052782 aluminium Inorganic materials 0.000 claims 13
- 229960005323 phenoxyethanol Drugs 0.000 claims 13
- 201000005702 Pertussis Diseases 0.000 claims 11
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 11
- 241000702670 Rotavirus Species 0.000 claims 9
- 208000002672 hepatitis B Diseases 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 239000002671 adjuvant Substances 0.000 claims 8
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 8
- 238000003756 stirring Methods 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 241000588650 Neisseria meningitidis Species 0.000 claims 5
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 5
- 229940001442 combination vaccine Drugs 0.000 claims 5
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 5
- 102000014914 Carrier Proteins Human genes 0.000 claims 4
- 108010078791 Carrier Proteins Proteins 0.000 claims 4
- 229960003983 diphtheria toxoid Drugs 0.000 claims 4
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims 4
- 238000001179 sorption measurement Methods 0.000 claims 4
- 229960000814 tetanus toxoid Drugs 0.000 claims 4
- 241000193738 Bacillus anthracis Species 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 3
- 108060000200 adenylate cyclase Proteins 0.000 claims 3
- 102000030621 adenylate cyclase Human genes 0.000 claims 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000000499 gel Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- -1 tetrafluoroborate Chemical compound 0.000 claims 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- 201000009182 Chikungunya Diseases 0.000 claims 2
- 208000004293 Chikungunya Fever Diseases 0.000 claims 2
- 101001120172 Crotalus durissus cumanensis Basic phospholipase A2 9 Proteins 0.000 claims 2
- 208000001490 Dengue Diseases 0.000 claims 2
- 206010012310 Dengue fever Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 2
- 101710154643 Filamentous hemagglutinin Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims 2
- 201000005505 Measles Diseases 0.000 claims 2
- 208000005647 Mumps Diseases 0.000 claims 2
- 239000012506 Sephacryl® Substances 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims 2
- 208000020329 Zika virus infectious disease Diseases 0.000 claims 2
- 208000002352 blister Diseases 0.000 claims 2
- 229940098773 bovine serum albumin Drugs 0.000 claims 2
- 230000021615 conjugation Effects 0.000 claims 2
- 208000025729 dengue disease Diseases 0.000 claims 2
- 238000005227 gel permeation chromatography Methods 0.000 claims 2
- 208000005252 hepatitis A Diseases 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 208000010805 mumps infectious disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 201000005404 rubella Diseases 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 101000585552 Bacillus anthracis Protective antigen Proteins 0.000 claims 1
- 241000588832 Bordetella pertussis Species 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101710082714 Exotoxin A Proteins 0.000 claims 1
- 101150047505 FIM1 gene Proteins 0.000 claims 1
- 241001446717 Galactia Species 0.000 claims 1
- 101000812705 Gallus gallus Endoplasmin Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 241000709701 Human poliovirus 1 Species 0.000 claims 1
- 102000008072 Lymphokines Human genes 0.000 claims 1
- 108010074338 Lymphokines Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 101710171321 Neuraminyllactose-binding hemagglutinin Proteins 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 101710183389 Pneumolysin Proteins 0.000 claims 1
- 108010013381 Porins Proteins 0.000 claims 1
- 101710194807 Protective antigen Proteins 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 1
- 229920005654 Sephadex Polymers 0.000 claims 1
- 239000012507 Sephadex™ Substances 0.000 claims 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101710182223 Toxin B Proteins 0.000 claims 1
- 101710182532 Toxin a Proteins 0.000 claims 1
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 claims 1
- 208000037386 Typhoid Diseases 0.000 claims 1
- SGSXWFDMRKAVLS-UHFFFAOYSA-N [6'-acetyloxy-5-[3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propylcarbamoyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl] acetate Chemical compound C1=C(C=2C(NC(=O)C=2C=2C3=CC=CC=C3N(C)C=2)=O)C2=CC=CC=C2N1CCCNC(=O)C(C=C1C(=O)O2)=CC=C1C12C2=CC=C(OC(C)=O)C=C2OC2=CC(OC(=O)C)=CC=C12 SGSXWFDMRKAVLS-UHFFFAOYSA-N 0.000 claims 1
- 239000011543 agarose gel Substances 0.000 claims 1
- 229940031416 bivalent vaccine Drugs 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000006599 congenital myasthenic syndrome 4C Diseases 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000001784 detoxification Methods 0.000 claims 1
- 229960004279 formaldehyde Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- SLPWXZZHNSOZPX-UHFFFAOYSA-N imidazole-1-carbonitrile Chemical compound N#CN1C=CN=C1 SLPWXZZHNSOZPX-UHFFFAOYSA-N 0.000 claims 1
- 208000037800 influenza D Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 229940092253 ovalbumin Drugs 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 108010021711 pertactin Proteins 0.000 claims 1
- 229960003742 phenol Drugs 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000007739 porin activity proteins Human genes 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 1
- 229960004906 thiomersal Drugs 0.000 claims 1
- 229960001005 tuberculin Drugs 0.000 claims 1
- 201000008297 typhoid fever Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021118038A JP2021181445A (ja) | 2016-08-26 | 2021-07-16 | 多価ワクチン組成物 |
| JP2023174503A JP2024009899A (ja) | 2016-08-26 | 2023-10-06 | 多価ワクチン組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621029037 | 2016-08-26 | ||
| IN201621029037 | 2016-08-26 | ||
| PCT/IB2017/055100 WO2018037365A1 (en) | 2016-08-26 | 2017-08-24 | Multivalent vaccine composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021118038A Division JP2021181445A (ja) | 2016-08-26 | 2021-07-16 | 多価ワクチン組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526635A JP2019526635A (ja) | 2019-09-19 |
| JP2019526635A5 true JP2019526635A5 (enExample) | 2019-10-31 |
| JP7384667B2 JP7384667B2 (ja) | 2023-11-21 |
Family
ID=60083359
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532214A Active JP7384667B2 (ja) | 2016-08-26 | 2017-08-24 | 多価ワクチン組成物 |
| JP2021118038A Pending JP2021181445A (ja) | 2016-08-26 | 2021-07-16 | 多価ワクチン組成物 |
| JP2023174503A Pending JP2024009899A (ja) | 2016-08-26 | 2023-10-06 | 多価ワクチン組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021118038A Pending JP2021181445A (ja) | 2016-08-26 | 2021-07-16 | 多価ワクチン組成物 |
| JP2023174503A Pending JP2024009899A (ja) | 2016-08-26 | 2023-10-06 | 多価ワクチン組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11235054B2 (enExample) |
| EP (1) | EP3503917B1 (enExample) |
| JP (3) | JP7384667B2 (enExample) |
| KR (1) | KR102607295B1 (enExample) |
| CN (1) | CN110691611A (enExample) |
| AU (1) | AU2017316768B2 (enExample) |
| CA (1) | CA3032901A1 (enExample) |
| CU (1) | CU24682B1 (enExample) |
| EA (1) | EA201900117A1 (enExample) |
| IL (1) | IL264605B2 (enExample) |
| MX (1) | MX2019001780A (enExample) |
| MY (1) | MY191163A (enExample) |
| PE (1) | PE20200004A1 (enExample) |
| PH (1) | PH12019500404B1 (enExample) |
| SG (1) | SG11201900365WA (enExample) |
| UA (1) | UA129115C2 (enExample) |
| WO (1) | WO2018037365A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY191163A (en) * | 2016-08-26 | 2022-06-03 | The Centers For Disease Control And Prevention Cdc | Multivalent vaccine composition |
| EP3621645A4 (en) | 2017-05-10 | 2021-01-27 | University of Massachusetts | BIVALENT VACCINES AGAINST DENGUE / HEPATITIS B |
| EA202190778A1 (ru) * | 2018-10-12 | 2021-08-05 | Серум Инститьют Оф Индия Прайват Лтд | Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения |
| JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2605179A1 (en) | 2005-04-18 | 2006-10-26 | Novartis Vaccines And Diagnostics, Inc. | Expressing hepatitis b virus surface antigen for vaccine preparation |
| JP5814507B2 (ja) * | 2006-09-07 | 2015-11-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| PE20100365A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion |
| CN102695522B (zh) | 2009-05-12 | 2016-10-19 | 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) | 新的人轮状病毒株和疫苗 |
| EP2661277A2 (en) * | 2011-01-05 | 2013-11-13 | Bharat Biotech International Limited | A combination heptavalent vaccine |
| WO2012117377A1 (en) * | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| UA125788C2 (uk) * | 2014-10-07 | 2022-06-08 | Серум Інстітют Оф Індія Прайвт Лімітед | Спосіб інактивації ентеровірусу, ад'ювант адсорбції та композиція із зменшеною дозою вакцини, одержана з ним |
| MY191163A (en) * | 2016-08-26 | 2022-06-03 | The Centers For Disease Control And Prevention Cdc | Multivalent vaccine composition |
-
2017
- 2017-08-24 MY MYPI2019001011A patent/MY191163A/en unknown
- 2017-08-24 US US16/327,513 patent/US11235054B2/en active Active
- 2017-08-24 CU CU2019000013A patent/CU24682B1/es unknown
- 2017-08-24 AU AU2017316768A patent/AU2017316768B2/en active Active
- 2017-08-24 JP JP2019532214A patent/JP7384667B2/ja active Active
- 2017-08-24 CA CA3032901A patent/CA3032901A1/en active Pending
- 2017-08-24 PE PE2019000409A patent/PE20200004A1/es unknown
- 2017-08-24 SG SG11201900365WA patent/SG11201900365WA/en unknown
- 2017-08-24 CN CN201780052380.5A patent/CN110691611A/zh active Pending
- 2017-08-24 WO PCT/IB2017/055100 patent/WO2018037365A1/en not_active Ceased
- 2017-08-24 UA UAA201902890A patent/UA129115C2/uk unknown
- 2017-08-24 IL IL264605A patent/IL264605B2/en unknown
- 2017-08-24 EA EA201900117A patent/EA201900117A1/ru unknown
- 2017-08-24 PH PH1/2019/500404A patent/PH12019500404B1/en unknown
- 2017-08-24 EP EP17783992.5A patent/EP3503917B1/en active Active
- 2017-08-24 MX MX2019001780A patent/MX2019001780A/es unknown
- 2017-08-24 KR KR1020197008377A patent/KR102607295B1/ko active Active
-
2021
- 2021-07-16 JP JP2021118038A patent/JP2021181445A/ja active Pending
-
2023
- 2023-10-06 JP JP2023174503A patent/JP2024009899A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013136397A (ru) | Комбинированная семивалентная вакцина | |
| JP2019526635A5 (enExample) | ||
| RU2013101418A (ru) | Комбинированная вакцина с ацеллюлярным коклюшем | |
| JP2020527571A5 (enExample) | ||
| RU2008112289A (ru) | Множественная вакцинация, включающая менингококки серогруппы с | |
| EP2682127A1 (en) | Vaccine | |
| JP2007516219A5 (enExample) | ||
| BRPI9710460B1 (pt) | composição imunogênica multi-valente e composição de vacina | |
| JP2021181445A (ja) | 多価ワクチン組成物 | |
| JP2012506420A (ja) | 全細胞百日咳を含む混合ワクチン | |
| RU2015111987A (ru) | Несшитые бесклеточные коклюшные антигены для применения в комбинированных вакцинах | |
| TWI880080B (zh) | 六合一液狀疫苗組成物 | |
| CN104039348B (zh) | 配制含有至少两种能够吸附到羟基氧化铝上的抗原的疫苗的方法 | |
| US11027005B2 (en) | Method for producing Hib conjugate vaccine using PRP with lowered molecular weight | |
| TH2001000286A (th) | องค์ประกอบก่อภูมิคุ้มกันที่มีความสเถียรซึ่งถูกปรับปรุง, สภาพก่อภูมิคุ้มกันที่เพิ่มขึ้น และสภาพก่อปฏิกิริยาที่ลดลงและกระบวนการสำหรับการเตรียมของสิ่งนั้น | |
| US11793869B2 (en) | Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | |
| EA043682B1 (ru) | Комбинированная вакцина и способ её производства (варианты) | |
| OA20569A (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof. | |
| OA21991A (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof. | |
| BR112019003419B1 (pt) | Vacina combinada e processo de fabricação de uma vacina combinada |